• Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
    • Armstrong AJ.
    • Clin Adv Hematol Oncol. 2022 Apr;20 Suppl 8(4):1-23.

    Review:

    Phase 3 MAGNITUDE Study: First Results of Niraparib With Abiraterone Acetate and Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With and Without Homologous Recombination Repair Gene Alterations.

    Review:

    PROpel: Phase III Trial of Olaparib and Abiraterone vs Placebo and Abiraterone as First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

    Commentary:

    Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.